Finally, when asked about moving toward a more cloud-based payroll service, Mucci said Paychex already has a software-as-a-service model, but also combines that with a dedicated payroll specialist to assist with any questions. He said that, ultimately, many companies will move their payroll functions to a cloud-based model, but Paychex remains a strong believer in also providing the specialists.
Cramer reiterated his buy on Paychex, saying the dividend pays investors to wait until hiring returns, at which time Paychex will be one stock headed to the moon.
A Healthy Regeneron
Inventing new drugs is still a great growth business, Cramer told viewers, but that business has moved away from the big pharma names of old and into a new generation of biotech companies including Regeneron (REGN - Get Report), a stock Cramer has touted for eight years for a gain of 3,400%.
Cramer said that despite the staggering growth over the past eight years, Regeneron is still a value stock -- it trades at just 30 times earnings despite a 29% annual growth rate. He said investors shouldn't let the stock's high share price deter them because this is one stock that still has plenty of room to grow.Regeneron's main product is Eylea, a best-in-class treatment for macular degeneration. The drug only requires half as many injections as its rivals and has been a huge hit with doctors and patients. But Regeneron isn't stopping there. The company has several new indications that Eylea could possibly treat, and it is hard at work exploring all of them. Beyond Eylea, there's also Regeneron's bowel cancer treatment, which only accounted for $31 million in sales for 2012 but is growing and just received approval in Europe. Regeneron is also working on anti-inflammatory drugs as well as anti-cholesterol, arthritis, dermatitis and asthma treatments. With all of these great opportunities in the works, Cramer said Regeneron is still on of his favorite biotech names.